{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:23:45Z","timestamp":1792787025148,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Romiplostim is a thrombopoietin\u2010mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6\u00a0months before romiplostim initiation through follow\u2010up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1440 patients in the UKITP Registry, 118 adults with primary ITP were eligible. Before romiplostim, 22% had splenectomy, 12% received platelet transfusion, 97% received\u00a0\u2265\u00a01 different ITP medication and 77% received\u00a0\u2265\u00a03. Most patients (73%) initiated romiplostim\u00a0\u2265\u00a01\u00a0year after ITP diagnosis (chronic phase). The mean duration of romiplostim treatment was 5.7 (SE 0.9) months, and the median was 1.4\u00a0months (IQR: 0.2, 6.5). Mean platelet count before romiplostim was 38\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/L, rising to 103\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/L within 1\u00a0month, and remaining 50\u2010150\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/L through up to 3\u00a0years of follow\u2010up. After romiplostim, 4% of patients had splenectomy, 6% received platelet transfusion, and 57% received just one ITP medication other than romiplostim.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study provides valuable insights into the real\u2010world use of romiplostim in primary ITP in routine practice and highlighted the timing of romiplostim initiation at different ITP disease phases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.13221","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T12:13:17Z","timestamp":1550059997000},"page":"416-423","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry"],"prefix":"10.1111","volume":"102","author":[{"given":"Indraraj Umesh","family":"Doobaree","sequence":"first","affiliation":[{"name":"Barts and The London School of Medicine and Dentistry London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newland","sequence":"additional","affiliation":[{"name":"Barts and The London School of Medicine and Dentistry London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"McDonald","sequence":"additional","affiliation":[{"name":"Barts and The London School of Medicine and Dentistry London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghava","family":"Nandigam","sequence":"additional","affiliation":[{"name":"Barts and The London School of Medicine and Dentistry London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Mensah","sequence":"additional","affiliation":[{"name":"Amgen Limited London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Leroy","sequence":"additional","affiliation":[{"name":"Center for Observational Research Amgen Limited London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouchka","family":"Seesaghur","sequence":"additional","affiliation":[{"name":"Center for Observational Research Amgen Limited London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitan","family":"Patel","sequence":"additional","affiliation":[{"name":"Amgen Limited Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Wetten","sequence":"additional","affiliation":[{"name":"Amgen Limited London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Provan","sequence":"additional","affiliation":[{"name":"Barts and The London School of Medicine and Dentistry London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.11.1630"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04547.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578336"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01247.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.3.909.415k02_909_913"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21616"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23262"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0084-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-010405"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0251-z"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-467068"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2549"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1974-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60203-2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60959-2"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60402-5"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14380"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00279-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0886-8"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13827"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23900"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1793-1"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12807"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13330"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-224766"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425512"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.098921"},{"key":"e_1_2_7_32_1","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000942\/WC500039537.pdf.Nplate Summary of Product Characteristics 2018. Accessed May 4 2018."},{"key":"e_1_2_7_33_1","unstructured":"https:\/\/www.nice.org.uk\/guidance\/ta221\/chapter\/1-Guidance.Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. National Institute for Health and Care Excellence 2014;Technology appraisal guidance [TA221]."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08377.x"},{"key":"e_1_2_7_35_1","first-page":"139","article-title":"Clinical characteristics and treatment pattern of newly diagnosed primary immune thrombocytopenia cases in the United Kingdom immune thrombocytopenia (ADULT) registry","volume":"101","author":"Doobaree IU","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_7_36_1","unstructured":"Copyright \u00a9 2017 Re\u2010used with the permission of The Health & Social Care Information Centre."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12794"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12359"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151886"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T19:17:22Z","timestamp":1694373442000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/ejh.13221"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13221","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"2018-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}